Related Experiment Video

Updated: Jul 15, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Xiaowei Qi1, Qiyun Shi1,2, Juncheng Xuhong1,3

  • 1Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, China.

Breast Cancer Research : BCR
|October 3, 2023
PubMed

Insights

Pyrotinib, an irreversible tyrosine kinase inhibitor (TKI), shows clinical effectiveness in treating HER2-positive breast cancer (BC). This review details pyrotinib-based therapies for HER2-positive BC in metastatic and neoadjuvant settings.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Science

Background:

  • Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is an aggressive subtype with poor prognosis.
  • HER2-targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs), and antibody-drug conjugates, have improved patient outcomes.
  • Small-molecule TKIs offer advantages like oral administration, better blood-brain barrier penetration for brain metastases, and reduced cardiotoxicity compared to monoclonal antibodies.

Purpose of the Study:

  • To review the development and clinical application of pyrotinib-based therapeutic approaches.
  • To highlight pyrotinib's role in treating HER2-positive breast cancer (BC) in various clinical settings.

Main Methods:

  • Review of clinical studies and literature on pyrotinib.
  • Analysis of pyrotinib's efficacy in metastatic and neoadjuvant settings for HER2-positive BC.
  • Comparison of pyrotinib's characteristics with other HER2-targeted therapies.

Main Results:

  • Pyrotinib, an irreversible pan-ErbB receptor TKI, has demonstrated clinical effectiveness.
  • Pyrotinib shows promise in both metastatic and neoadjuvant treatment of HER2-positive BC.
  • Pyrotinib offers potential advantages in oral administration and managing brain metastases.

Conclusions:

  • Pyrotinib represents a significant advancement in the treatment of HER2-positive breast cancer.
  • Pyrotinib-based therapies are valuable options for patients with HER2-positive BC, particularly those with brain metastases.
  • Further research and clinical application of pyrotinib are warranted to optimize its use in breast cancer management.
Keywords:
Breast cancerHER-2 positivePyrotinibTargeted therapyTyrosine-kinase inhibitor

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203